27 results about "Avian virus" patented technology

The application belongs to the technical field of biology, and discloses a kind of H5 subtype avian influenza virus HA protein self-assembly nanoparticle and its application, molecular adjuvant Gp96-N and application, nanoparticle vaccine.The self-assembly nanoparticle has good immunological efficacy, and the molecular adjuvant Gp96-N has good immune enhancement effect.The animal test result of the application shows that the nanoparticle vaccine has good immunological efficacy, which is significantly stronger than the trimer subunit vaccine.10 μg HA-I53_dn5 nanoparticle can induce high level, balanced and durable immune response after single immunization.The result of low-dose test further confirms the immunological efficacy of the nanoparticle vaccine, and 5 μg or 2.5 μg HA-I53_dn5 nanoparticle can still provide complete protection against lethal challenge of heterologous epidemic virulent strain.Meanwhile, the combination of Gp96-N molecular adjuvant can further improve the level of immune response and the cross-protection efficacy of low-dose nanoparticle.

The present disclosure is directed to antibodies binding to and neutralizing avian H5N1 influenza virus and methods for use thereof.

The utility model provides a kind of for preventing avian influenza's medicine spraying device, belong to spraying device field, including base, medicine jar, rotating shaft, big bevel gear, motor, water pump and spraying assembly, medicine jar and water pump are respectively arranged on base, and one end of water pump is connected with the bottom of medicine jar one side, the other end of water pump is connected with spraying assembly, the top of medicine jar is provided with jar cover, rotating shaft rotation is set in the middle part of jar cover, big bevel gear is set on one end of rotating shaft, the other end of rotating shaft extends to the inside of medicine jar, rotating shaft in medicine jar inside is intervally provided with several clean water spray head and cleaning assembly, rotating shaft is set as hollow shaft, motor is set in the top of jar cover one side, the output of motor is provided with small bevel gear, small bevel gear is engaged with big bevel gear, the bottom end of base is respectively provided with self-locking universal wheel.The utility model is cleaned by the cleaning assembly and clean water spray head of rotating shaft to the medicine in medicine jar wall residual drug.

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

This invention provides a microfluidic chip for the multiplex differentiation and diagnosis of different avian influenza virus subtypes and its application. Specifically, it is a microfluidic chip based on TaqMan probes that can simultaneously and rapidly differentiate and diagnose 25 avian influenza subtypes, enabling high-throughput simultaneous detection of multiple gene targets. This invention utilizes high-throughput microfluidic chip technology to simplify the differential diagnosis procedure for avian influenza virus subtypes, resulting in more accurate and time-saving results. It is more suitable for rapid clinical diagnosis of avian influenza, providing technical support for rapid clinical detection, diagnosis, and prevention of avian influenza, and is of great significance for epidemic prevention and control and safeguarding public health security.

The application provides a microfluidic chip for diagnosing avian influenza H3 / H5 / H6 / H9 molecular typing based on microfluidics and a use method, relates to the field of pathogenic microorganism testing technology, and improves the efficiency, accuracy and convenience of avian influenza molecular diagnosis, promotes the development of molecular diagnosis technology, and uses the microfluidic chip body to be supported and used through the chip support, opens the protection layer attached to the microfluidic chip body by means of the light-proof assembly on the side, and can provide a light-proof environment again during and after the detection process, and can maintain a longer detection state.

The present invention provides recombinant viral vectors containing and expressing antigens of avian pathogens, compositions comprising said recombinant viral vectors, and polyvalent vaccines comprising them. The present invention also provides methods for vaccination against various avian pathogens and a method for producing the recombinant viral vectors.

The application belongs to the technical field of biological detection, and particularly relates to a combination of monoclonal antibodies against hemagglutinin protein of avian influenza virus H9 subtype and application thereof. The combination comprises monoclonal antibodies 5E2 and 1F3, the CDR sequences of the heavy chain and light chain variable regions of which are clear, and are shown as SEQ ID NO. 1-12 respectively, ensuring high affinity and specific recognition of H9-HA protein. The antibody combination is suitable for constructing a colloidal gold immunochromatographic detection test strip, wherein 5E2 is used as a capture antibody for membrane drawing, and 1F3 is used as a labeled antibody for gold labeling. The technical scheme effectively solves the problem of cross-reaction with other HA subtypes (such as H5 and H7) caused by poor antibody specificity of the existing detection means. The sensitivity of the test strip to H9-HA recombinant protein can reach 1 ng / mL, and there is no cross-reaction, so the test strip is suitable for on-site rapid screening and large-scale monitoring of avian influenza virus H9 subtype.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody combination that specifically recognizes the hemagglutinin protein of the H6 subtype of avian influenza virus and its applications. The antibody combination consists of monoclonal antibodies 2D12 and 4G3, targeting different epitopes of the H6 hemagglutinin protein, and possesses clearly defined heavy and light chain variable region complementarity-determining region sequences, as shown in SEQ ID NO. 1-12, respectively. The antibody combination exhibits high specificity and affinity, effectively avoiding cross-reactivity with other influenza subtypes such as H1, H5, H7, and H9, as well as common avian pathogens. The colloidal gold test strip constructed based on this antibody combination is highly sensitive and easy to operate, suitable for in vitro detection and epidemiological screening of the H6 subtype of avian influenza virus. It solves the false positive problem caused by cross-reactivity in existing technologies, providing a reliable technical means for the monitoring and quarantine of the H6 subtype of virus.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody for resisting avian influenza virus H7 subtype hemagglutinin protein and application. The amino acid sequence of a heavy chain variable region CDR of the monoclonal antibody 1F4 is shown as SEQ ID NO.1-3, the amino acid sequence of a light chain variable region CDR of the monoclonal antibody 1F4 is shown as SEQ ID NO.4-6, and the heavy chain variable region, the light chain variable region and coding nucleotide sequences of the monoclonal antibody 1F4 are clear. The monoclonal antibody has high specificity and good affinity, can effectively distinguish the H7 subtype from other influenza virus subtypes, and has no cross reaction. The invention also provides application of the colloidal gold test strip in preparation of a recognition tool, the constructed colloidal gold test strip takes 1F4 as a capturing and labeling antibody, is simple and convenient to operate, visual in result and suitable for on-site rapid screening and large-scale monitoring, and provides technical support for prevention and control of H7 subtype avian influenza.

This invention discloses a primer composition, kit, and application for avian pathogens. The primer composition comprises a crRNA with the sequence shown in SEQ ID NO: 1, an RT-RAA upstream primer with the sequence shown in SEQ ID NO: 2, and an RT-RAA downstream primer with the nucleotide sequence shown in SEQ ID NO: 3. It may also include a fluorescent probe with the sequence TTTTT. This primer composition can be used for the detection of avian infectious bronchitis virus, exhibiting high specificity and no cross-reactivity with common avian viruses such as avian influenza virus, Newcastle disease virus, and infectious laryngotracheitis virus. Furthermore, the primer composition has high sensitivity, with a detection limit as low as 4.25 × 10⁻⁶. 2 The primer composition exhibits high copy number / μL, good reproducibility, and stable results. It is suitable for single-tube isothermal nucleic acid amplification detection, offering mild reaction conditions and significantly reduced detection time, demonstrating excellent industrial application value.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody against hemagglutinin protein of H7 subtype of avian influenza virus and application. The CDR amino acid sequences of the heavy chain variable region of the monoclonal antibody 1F4 are shown as SEQ ID NO. 1-3, the CDR amino acid sequences of the light chain variable region are shown as SEQ ID NO. 4-6, and the heavy chain, the light chain variable region and the coding nucleotide sequence are clear. The monoclonal antibody has high specificity and good affinity, can effectively distinguish the H7 subtype from other influenza virus subtypes, and has no cross reaction. The application also provides application of the monoclonal antibody in preparation of a recognition tool, and the constructed colloidal gold detection test strip takes the 1F4 as a capture and label antibody, is simple and convenient to operate, the result is intuitive, is suitable for on-site rapid screening and large-scale monitoring, and provides technical support for prevention and control of the H7 subtype of avian influenza.

This invention belongs to the field of biotechnology and relates to a monoclonal antibody 1F8 against the hemagglutinin protein of H5 subtype avian influenza virus and its applications. This invention provides a monoclonal antibody against the hemagglutinin protein of H5 subtype avian influenza virus, capable of recognizing the H5 subtype avian influenza virus. The monoclonal antibody subtype is IgG2a, κ, named 1F8, and specifically recognizes the hemagglutinin protein of the H5 subtype avian influenza virus. The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID No. 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID No. 4. The advantages of this invention are that it provides a monoclonal antibody against the hemagglutinin protein of H5 subtype avian influenza virus. The preparation method is simple and easy to implement. More importantly, the monoclonal antibody prepared by this method can have multiple applications, such as qualitative diagnosis of H5 subtype avian influenza samples in clinical and laboratory settings.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for specifically recognizing hemagglutinin protein of avian influenza virus H6 subtype and a use thereof. The antibody combination is composed of monoclonal antibodies 2D12 and 4G3, is directed to different epitopes of the H6 hemagglutinin protein, has clear heavy chain and light chain variable region complementarity determining region sequences, and is respectively shown as SEQ ID NO. 1-12. The antibody combination has high specificity and affinity, and can effectively avoid cross reactions of other influenza subtypes such as H1, H5, H7 and H9 and common avian pathogens. A colloidal gold detection test strip based on the antibody combination has high sensitivity and simple operation, is suitable for in vitro detection and epidemiological screening of the H6 subtype avian influenza virus, solves the false positive problem caused by cross reactions in the prior art, and provides a reliable technical means for monitoring and quarantine of the H6 subtype virus.

The present invention relates to the field of biological vaccine research and development technology, and in particular, to a VSV vector-based highly pathogenic H5 subtype avian influenza inactivated vaccine and a method for preparing same. The method comprises: using a vesicular stomatitis virus with the deletion of the surface envelope protein gene as a vector, inserting the NA gene and the HA gene of an H5 subtype highly pathogenic avian influenza virus strain between the M gene and the L gene of the vector in the form of an expression cassette, and acquiring a recombinant virus by means of rescue via reverse genetic technology; inoculating the recombinant virus into susceptible cells, culturing for replication and proliferation, and then harvesting a viral solution; inactivating the viral solution to acquire an inactivated viral solution; and adding the inactivated viral solution to a pharmaceutically or veterinarily acceptable carrier, excipient, medium, or adjuvant to acquire an inactivated vaccine. The provided H5 subtype avian influenza inactivated vaccine can induce a high hemagglutination inhibition titer of avian influenza virus on day 21 after chick immunization. The provided inactivated vaccine has good safety and immunogenicity.

This invention provides a modified hemagglutinin (HA) protein for preparing a broad-spectrum vaccine against H9 avian influenza, a broad-spectrum vaccine based on the HA protein, a preparation method, and applications. The modified HA protein is obtained through the following strategy: consensus sequences are constructed as immunogenic backbones for the HA sequences of H9 avian influenza viruses at different epidemic periods; based on this, two types of functional mutations are directionally introduced: one type involves transplanting key epitope residues targeted by known broad-spectrum antibodies, and the other type involves neutralizing epitope residues predicted based on viral evolutionary patterns. The modified HA protein of this invention can maintain a highly similar overall fold and trimer interface to the wild type, can be efficiently expressed in eukaryotic systems, and can induce high levels of neutralizing antibodies with broad-spectrum cross-protective effects in target animals. It provides a core antigen candidate for the development of a new generation of H9 broad-spectrum vaccines and has broad application prospects.

The present application relates to a strain of Bacteroides fragilis and its application, the strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 14, 2026, and the preservation number is: CGMCC No. 38257.The strain can regulate STING-dependent training immunity, effectively resist Salmonella typhimurium and H9N2 avian influenza virus infection, maintain the integrity of the intestinal barrier of the host, and reduce inflammatory damage.The Bacteroides fragilis of the present application has good biological safety, and the strain can be used as a training immunity inducer, and the strain is expected to be a candidate probiotic or vaccine adjuvant for preventing / treating bacterial and viral infections, suitable for human health and poultry farming, and provides a new solution to resist antibiotic resistance.

The present application relates to the technical field of rapid detection of H5N1 avian influenza virus, and particularly relates to a nucleic acid releasing agent for H5N1 virus, and a preparation method and application thereof.The nucleic acid releasing agent is composed of the following components with a mass ratio of (50-80):1:(3.9-12.5):(0.02-0.25):(15-63):(12-20):(10-87): guanidine hydrochloride solution, TritonX-100, isopropyl alcohol, Tween-20, ethanol, EDTA and DEPC water.The nucleic acid releasing agent provided by the present application can efficiently release viral nucleic acid and remove interfering substances, and lays a foundation for detecting samples with low viral load;then, in combination with primer screening, reaction system and freeze-drying condition optimization, a visual freeze-drying RT-RAA detection system is constructed, and finally, rapid, sensitive, specific and visual detection of H5N1 virus is realized.

This invention relates to the fields of veterinary immunology and molecular biology, and discloses a chicken cytokine composition with immune-enhancing effects and its applications. The immune-enhancing chicken cytokine composition includes recombinant chicken cytokines IL-9 and IL-21, whose amino acid sequences are shown in SEQ ID NO.4 and SEQ ID NO.8, respectively. These two cytokines can upregulate the expression of IL-1β, IL-2, IL-4, IL-6, IFN-γ, IL-17A, and TNF-α in chicken PBMCs, stimulating Th1, Th2, and Th17 immune responses in chickens. When used in combination with a Newcastle disease-avian influenza bivalent inactivated vaccine, this recombinant chicken cytokine composition exhibits a significant immune-enhancing effect and has potential application prospects. This chicken cytokine composition has advantages such as ease of preparation, high yield, good stability, and low production cost.

This invention relates to the field of disease treatment, specifically providing the use of AMBRA1 inhibitors in the preparation of medicaments for the prevention and / or treatment of influenza virus infection, as well as methods for screening drugs. AMBRA1 is involved in the replication of multiple types of influenza viruses, including seasonal influenza A and influenza B, as well as avian influenza H5N1, H5N6, and H9N2, and is a broad-spectrum influenza host factor, providing candidate drug targets for the development of broad-spectrum anti-influenza drugs.

The application belongs to the technical field of biological detection, and particularly relates to a combination of monoclonal antibodies for avian influenza virus H5 subtype hemagglutinin protein and application thereof. The combination can specifically recognize avian influenza virus H5-HA protein, wherein the heavy chain and light chain variable region complement determining region (CDR) sequences of 2B8 and 6B5 are clear (as shown in SEQ ID NO. 1-12, respectively), which ensures the high affinity and specific binding capacity of the antibody combination. The combination is applied to the construction of a colloidal gold immunochromatographic detection test strip, and provides a stable and reliable biological recognition tool for rapid and accurate detection of avian influenza virus H5. The colloidal gold detection test strip constructed based on the combination has a detection sensitivity as high as 1 ng / mL, and is simple to operate without the need of complex instruments, and can be judged within 20 minutes, thereby providing reliable technical support for early warning, on-site rapid screening and monitoring of H5 subtype avian influenza.

This invention belongs to the field of nanobody technology and provides a method for preparing and applying a single-domain antibody against avian influenza virus H9N2. The application involves using this H9N2 single-domain antibody in the prevention and control of avian influenza virus H9N2. The invention prepares the H9N2 single-domain antibody by immunizing striped bamboo sharks and collecting their tail vein blood. The purity and stability of the H9N2 single-domain antibody were evaluated. The results show that the recombinant single-domain antibody targeting the H9N2 virus HA protein prepared in this invention has high purity and good activity, exhibits good in vitro binding activity with H9N2, and shows good stability at room temperature. The recombinant single-domain antibody 28-H9N2-2SP4H can recognize and bind to the H9N2 virus on the surface of MDCK cell membranes, providing a new direction for the prevention and control of avian influenza as an alternative to traditional antibodies.

The application belongs to the technical field of biological detection, and particularly relates to a combination of monoclonal antibodies against hemagglutinin protein of avian influenza virus H9 subtype and application thereof. The combination comprises monoclonal antibodies 5E2 and 1F3, the CDR sequences of the heavy chain and light chain variable regions of which are clear, and are shown as SEQ ID NO. 1-12 respectively, ensuring high affinity and specific recognition of H9-HA protein. The antibody combination is suitable for constructing a colloidal gold immunochromatographic detection test strip, wherein 5E2 is used as a capture antibody for membrane drawing, and 1F3 is used as a labeled antibody for gold labeling. The technical scheme effectively solves the problem of cross-reaction with other HA subtypes (such as H5 and H7) caused by poor antibody specificity of the existing detection means. The sensitivity of the test strip to H9-HA recombinant protein can reach 1 ng / mL, and there is no cross-reaction, so the test strip is suitable for on-site rapid screening and large-scale monitoring of avian influenza virus H9 subtype.

The application belongs to the field of biology, and discloses an AIV MHC-BF2*1901 restrictive epitope peptide, and the amino acid sequence of the epitope peptide is shown in any one of SEQ ID NO. 1, SEQ ID NO. 3 to SEQ ID NO. 18. 23 chicken MHC I molecule BF2*1901 restrictive avian influenza virus CTLs are successfully screened, and 21 peptides are newly identified CTL epitopes in the research. The application can identify weak binding peptides and non-typical length super short peptides which do not conform to the motif, the peptides are easy to be misjudged or missed by traditional methods, but have immunogenicity. Meanwhile, the application solves the limitation that a large number of haplotype chicken immune cells are needed in the traditional screening method, and the use of tag antibodies instead of chicken MHC I monoclonal antibodies significantly reduces the cost of CTL epitope screening, and provides a fast, economical and effective CTL epitope screening technology for avian influenza virus vaccine design and research on cellular immune mechanism. Meanwhile, the application also discloses nucleic acid molecules and application.